Shire Pharmaceuticals Group Plc

Fosrenol shown to reduce and maintain serum phosphate levels up to 3 years

Published in Pharma Law Weekly, November 22nd, 2005

A published study in the October 2005 issue of Nephron Clinical Practice shows Fosrenol (lanthanum carbonate) successfully reduces and maintains mean serum phosphate levels for up to 3 years, while demonstrating safety and tolerability in patients with end-stage renal disease (ESRD).

The results are from study extensions initially involving 518 and 161 patients treated with Fosrenol for periods of up to 1 and 3 years, respectively. Prior to the extensions, those patients taking Fosrenol were continued on the treatment, and those receiving calcium carbonate were switched to Fosrenol.

At the end of the first, 6-month study extension, the mean...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry